Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

What sets sarclisa apart from other cd38 targeted therapies?

See the DrugPatentWatch profile for sarclisa

How Sarclisa Differs from Darzalex in Mechanism and Structure

Sarclisa (isatuximab-irfc) and Darzalex (daratumumab) both target CD38 on multiple myeloma cells, but Sarclisa has a distinct Fc domain that enables stronger antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Darzalex relies more on complement-dependent cytotoxicity (CDC). Sarclisa also binds a unique epitope on CD38, allowing it to inhibit CD38 enzymatic activity more effectively, which reduces adenosine production—a factor that can suppress immune responses in tumors.[1][2]

Clinical Outcomes: Progression-Free Survival Edge in Key Trials

In the ICARIA-MM trial, Sarclisa plus pomalidomide and dexamethasone extended median progression-free survival to 11.9 months versus 6.5 months for pomalidomide-dexamethasone alone, with a 40% reduction in progression risk. Darzalex combinations like CASTOR (with bortezomib-dex) showed 16.7 months PFS, but head-to-head data is limited. Sarclisa stands out in later-line refractory settings, with faster infusion times (3 hours initially, then 75 minutes) compared to Darzalex's longer infusions.[1][3]

Administration and Patient Convenience Factors

Sarclisa requires fewer premedications—no antivirals or longer steroids—reducing infection risks and simplifying outpatient use. Its subcutaneous formulation is in development, unlike Darzalex's IV-only approval (though a subQ version exists). This appeals to patients tired of lengthy infusions.[2][4]

Who Makes Sarclisa and Its Competitive Landscape

Sanofi developed Sarclisa, approved by FDA in March 2020 for relapsed/refractory multiple myeloma after 4+ prior lines. Darzalex, from Johnson & Johnson, entered earlier (2015) and dominates with broader indications, including frontline use. No other CD38 therapies like felzartamab (Bayer, more for kidney disease) compete directly in myeloma yet.[1][5]

Patent and Market Exclusivity Timeline

Sarclisa's key composition-of-matter patent (US 8,562,991) expires in 2028, with formulation patents into 2033. Darzalex faces biosimilar challenges sooner, with patents expiring 2029-2031 amid ongoing litigation. This gives Sarclisa a window for expansion before generics.[6]

[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761174s000lbl.pdf
[2] NCCN Guidelines, Multiple Myeloma v. 2.2023
[3] ICARIA-MM Trial, Lancet Oncology 2019
[4] Sanofi Prescribing Information
[5] Drugs.com Approval Database
[6] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/SARCLISA



Other Questions About Sarclisa :

How does sarclisa's efficacy differ from other cd38 antibodies? What are the differences in effectiveness between sarclisa and other cd38 antibodies? How does sarclisa compare to other cd38 antibodies in treating multiple myeloma? How does sarclisa's efficacy differ from other cd38 antibodies? How does sarclisa impact patient outcomes compared to other cd38 antibodies? Can you explain sarclisa's antibody engineering process? How does sarclisa's efficacy differ from other cd38 antibodies?




DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2026. All rights reserved. Privacy